| Identification | Back Directory | [Name]
CID 2745687 | [CAS]
264233-05-8 | [Synonyms]
CID 2745687
Methyl 1-(2,4-Difluoro-phenyl)-5-((4-tert-butyl-thioseMicarbazono)Methyl)-1H-pyrazole-4-carboxylate
methyl 5-[(E)-(tert-butylcarbamothioylhydrazono)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate
1H-Pyrazole-4-carboxylic acid, 1-(2,4-difluorophenyl)-5-[[2-[[(1,1-dimethylethyl)amino]thioxomethyl]hydrazinylidene]methyl]-, methyl ester | [Molecular Formula]
C17H19F2N5O2S | [MDL Number]
MFCD00111058 | [MOL File]
264233-05-8.mol | [Molecular Weight]
395.43 |
| Hazard Information | Back Directory | [Description]
GPR35 is a G protein-coupled receptor that is activated by kynurenic acid and 2-acyl lysophosphatidic acids (e.g., 2-oleoyl lysophosphatidic acid). It is expressed predominantly on immune cells, the brain, and in the gastrointestinal tract. GPR35 is overexpressed in gastric cancer cells. CID-2745687 is a reversible, competitive antagonist of GPR35, blocking activation by the synthetic agonist pamoic acid with a Ki value of 12.8 nM. It less potently blocks activation of GPR35 by zaprinast (IC50 = 160 nM). It shows ~57-fold selectivity for GPR35 over the related receptor GPR55 (IC50 = 9.08 μM). | [Uses]
CID 2745687 is used as a GPR35 antagonist, with potential application towards immune or gastrointestinal system regulation.
| [Definition]
ChEBI: 5-[[[(tert-butylamino)-sulfanylidenemethyl]hydrazinylidene]methyl]-1-(2,4-difluorophenyl)-4-pyrazolecarboxylic acid methyl ester is a ring assembly and a member of pyrazoles. | [in vitro]
previous study indicated that both cid-2745687 and ml-145 could competitively inhibit the effects of cromolyn disodium and zaprinast (two agonists sharing an overlapping binding site) on human gpr35. in contrast, though ml-145 antagonized the effects of pamoate competitively, cid-2745687 showed a noncompetitive fashion. additionally, neither ml-145 nor cid-2745687 was able to antagonize the agonist effects at rodent ortholog of gpr35 [1]. | [in vivo]
to test whether gpr35 contributes to the metabolic effect of zaprinast, the retina from cngb1/ mice was preincubated with a gpr35 antagonist, cid-2745687, followed by an additional zaprinast treatment. results showed that cid-2745687 did not block the effect of zaprinast on glutamate and aspartate. moreover, pamoic acid, the gpr35 agonist, did not change aspartate or glutamate levels [1]. | [storage]
Store at -20°C | [References]
[1] jenkins l,harries n,lappin je,mackenzie ae,neetoo-isseljee z,southern c,mciver eg,nicklin sa,taylor dl,milligan g. antagonists of gpr35 display high species ortholog selectivity and varying modes of action. j pharmacol exp ther.2012 dec;343(3):683-95.
[2] du j,cleghorn wm,contreras l,lindsay k,rountree am,chertov ao,turner sj,sahaboglu a,linton j,sadilek m,satrústegui j,sweet ir,paquet-durand f,hurley jb. inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. j biol chem.2013 dec 13;288(50):36129-40. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|